Immunity War: A Novel Therapy for Lymphoma Using T-cell Bispecific Antibodies.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29884742.
- Also identified by DOI 10.1158/1078-0432.CCR-18-1363.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL). <i>Clin Cancer Res; 24(19); 4631-2. ©2018 AACR</i> <i>See related article by Bacac et al., p. 4785</i>.
Medical subject headings
- Antibodies, Bispecific
- Hematologic Neoplasms
- Lymphoma